F 182112
Alternative Names: F-182112Latest Information Update: 28 Jan 2026
At a glance
- Originator Lunan Pharmaceutical Group
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Multiple myeloma
Most Recent Events
- 28 Jan 2026 No recent reports of development identified for phase-I development in Multiple-myeloma(Second-line therapy or greater) in China (IV, Infusion)
- 12 Jun 2025 Updated efficacy and adverse events data from a phase I trial in Multiple myeloma presented at the 30th Congress of the European Haematology Association (EHA-2025)
- 28 Aug 2024 No recent reports of development identified for phase-I development in Multiple-myeloma(In the elderly, Refractory metastatic disease, Second-line therapy or greater, In adults) in China (IV, Infusion)